5-N-(2-aminopropyl)-7-N-benzyl-2H-triazolo[4,5-d]pyrimidine-5,7-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 5-N-(2-aminopropyl)-7-N-benzyl-2H-triazolo[4,5-d]pyrimidine-5,7-diamine
• 化学式: C₁₄H₁₈N₈
• 分子量: 298.35
• InChiKey: HLBIKJSDPUSYNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Azapurine derivatives
  申请人：Fuksova Kveta

  公开号：US20060035909A1

  公开（公告）日：2006-02-16

  The present invention relates to a compound of formula I, or a pharmaceutically acceptable acid salt thereof. The invention further relates to the use of said compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi or protists, or Alzheimer's disease. Further aspects of the invention relate to the use of such compounds in the inhibition of cell proliferation, in the induction of apoptosis, to modulate the activity of adrenergic and/or purinergic receptors or to suppress immunostimulation. The invention also relates to the use of 2,6,9-trisubstituted 8-azapurines in maintaining mammalian ooctyes at the germinal vesicle stage.

  本发明涉及式I的化合物或其药学上可接受的酸盐。本发明进一步涉及使用该化合物治疗过度增生性皮肤疾病、病毒感染、癌症、类风湿性关节炎、狼疮、I型糖尿病、多发性硬化症、再狭窄、多囊肾病、移植排斥、移植物抗宿主病和痛风，或用于治疗牛皮癣、由真菌或原生生物引起的寄生虫病或阿尔茨海默病。本发明的其他方面涉及使用这些化合物抑制细胞增殖，诱导细胞凋亡，调节肾上腺素能和/或嘌呤能受体的活性或抑制免疫刺激。本发明还涉及使用2,6,9-三取代8-氮杂嘌呤维持哺乳动物卵母细胞处于生殖泡阶段。
• AZAPURINE DERIVATIVES
  申请人：INSTITUTE OF EXPERIMENTAL BOTANY ASCR

  公开号：EP1539760A2

  公开（公告）日：2005-06-15
• US7816350B2
  申请人：——

  公开号：US7816350B2

  公开（公告）日：2010-10-19
• [EN] AZAPURINE DERIVATIVES<br/>[FR] DERIVES D'AZAPURINE
  申请人：INST OF EX BOTANY ASCR

  公开号：WO2004018473A2

  公开（公告）日：2004-03-04

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable acid salt thereof. The invention further relates to the use of said compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi or protists, or Alzheimer's disease. Further aspects of the invention relate to the use of such compounds in the inhibition of cell proliferation, in the induction of apoptosis, to modulate the activity of adrenergic and/or purinergic receptors or to suppress immunostimulation. The invention also relates to the use of 2,6,9-trisubstituted 8-azapurines in maintaining mammalian ooctyes at the germinal vesicle stage.